| Clinical Trial Name | Clinical Trial Full Title | Principal Investigator | Project site status | Clinical trials gov number |
|---|---|---|---|---|
| (AstraZeneca) D933SC00001 / NILE | A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer | Hotte, Dr Sebastien | Open to recruitment | NCT03682068 |
| (BMS) CA209-73M | A Phase 2, Single-arm Open-label Study of Combination Nivolumab and Ipilimumab Retreatment in Advanced Renal Cell Carcinoma Patients Progressing on Nivolumab Maintenance Therapy After Nivolumab and Ipilimumab Induction. | Hotte, Dr Sebastien | Open to recruitment | NCT04088500 |
| (CCTG) BL.13 | A Randomized Phase II Trial Assessing Trimodality Therapy With or Without Adjuvant Durvalumab (MEDI4736) to Treat Patients with Muscle-Invasive Bladder Cancer | Lalani, Dr Aly-Khan | Open to recruitment | NCT03768570 |
| (CCTG) IND.234 / PC-BETS - Master Protocol | Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol | Mukherjee, Dr Som | Open to recruitment | NCT03385655 (Master) |
| (CCTG) IND.234 / PC-BETS - Sub-Study IND.223 | A Phase II Study of Palbociclib, A CDK4/6 Inhibitor, in Patients With Metastatic Castration-Resistant Prostate Cancer | Mukherjee, Dr Som | Open to recruitment | NCT02905318 |
| (CCTG) IND.234A/PC-BETS Sub-Study A | A Phase II Study of AZD1775, A WEE1 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open to recruitment | NCT03385655 (A) |
| (CCTG) IND.234B/PC-BETS Sub-Study B | A Phase II Study of Savolitinib, A CMET Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open to recruitment | NCT03385655(B) |
| (CCTG) IND.234C/PC-BETS Sub-Study C | A Phase II Study of Darolutamide (ODM-201) in Patients with Metastatic Castration-Resistant Prostate Cancer Previously Treated with Abiraterone Acetate or Enzalutamide - A Sub-Study of IND.234 | Mukherjee, Dr Som | Open to recruitment | NCT03385655(C) |
| (CCTG) IND.234D/PC-BETS Sub-Study D | A Phase II Study of CFI-400945 Fumarate in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Mukherjee, Dr Som | Open to recruitment | NCT03385655(D) |
| (CCTG) IND.234E/PC-BETS Sub-Study E | A Phase II Study of Ipatasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients with PI3K Pathway Alterations in Circulating Tumour DNA (ctDNA) | Mukherjee, Dr Som | Open to recruitment | NCT03385655(E) |
| (CCTG) IND.234F/PC-BETS Sub-Study F | A Phase II Study of Durvalumab and Tremelimumab in Metastatic Castration-Resistant Prostate Cancer | Mukherjee, Dr Som | Open to recruitment | NCT03385655 (F) |
| (CCTG) IND.234G/PC-BETS Sub-Study G | A Phase II Study of Carboplatin in Patients with Metastatic Castration-Resistant Prostate Cancer | Mukherjee, Dr Som | Open to recruitment | NCT03385655 (G) |
| (CCTG) PR.20 | A Randomized Phase III Trial of Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (PLATON) | Quan, Dr Kimmen | Open to recruitment | NCT03784755 |
| (EXELIXIS) XL184-315 / CONTACT-02 | A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL 184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy(NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer. | Hotte, Dr Sebastien | Open to recruitment | NCT04446117 |
| (JCC) Prostate HBI | Non-Targeted Low Dose Radiotherapy For Recurrent Prostate Cancer | Dayes, Dr Ian | Open to recruitment | NCT03196778 |
| (JCC) The PBS Study | A randomized phase II trial investigating Stereotactic Body RadioTherapy (SBRT) for prostate boost irradiation in the treatment of high risk Prostate Cancer (PrCa) | Tsakiridis, Dr Theos | Open to recruitment | NCT03380806 |
| (JGH) PCS IX / PCS 9 | The Role of Stereotactic Body Radiotherapy in the Management of Castration-Resistant Prostate Cancer With Oligometastases: An Adaptive Phase II/III Randomized Trial. | Tsakiridis, Dr Theos | Open to recruitment | NCT02685397 |
| (Merck) MK-3475-641 / KEYNOTE 641 | A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Lalani, Dr Aly-Khan | Open to recruitment | NCT03834493 |
| (Merck) MK-3475-921 / KEYNOTE 921 | A Phase 3, Randomized, Double-blind Study of Pembrolizumab (MK-3475) Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC) who have Progressed on a Next Generation Hormonal Agent (NHA) | Lalani, Dr Aly-Khan | Open to recruitment | NCT03834506 |
| (Merck) MK-6482-005 | An Open-label, Randomized Phase 3 Study of MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies | Lalani, Dr Aly-Khan | Open to recruitment | NCT04195750 |
| (Merck) MK-7339-010 / KEYLYNK-010 | Phase 3, Randomized, Open-label Study of Pembrolizumab (MK-3475) Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) Who are Unselected for Homologous Recombination Repair Defects and Have Failed Prior Treatment with One Next-generation Hormonal Agent (NHA) and Chemotherapy | Lalani, Dr Aly-Khan | Open to recruitment | NCT03834519 |
| (Merck) MK-7902-011 / LEAP-011 / E7080 | A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Matching Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011) | Lalani, Dr Aly-Khan | Open to recruitment | NCT03898180 |
| (UHN) WI222910 / ALPACA | A Phase 2, Multi-centre, Open-label Study of Avelumab (MSB0010718C) in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based Chemotherapy or Progressed On or After Platinum-based Chemotherapy | Mukherjee, Dr Som | Open to recruitment | NCT03391479 |
| OCOG-2013-PETMUSE | Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging | Mukherjee, Dr Som | Open to recruitment | NCT02462239 |
| OCOG-2019-CYTOSHRINK / CA209-7DR | Cytoreductive Stereotactic Hypofractionated Radiotherapy With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer | Lalani, Dr Aly-Khan | Open to recruitment | NCT04090710 |
| (Basilea) DZB-CS-201 / FIDES-02 | An open-label multi-cohort Phase 1b/2 study of derazantinib and atezolizumab in patients wtih urothelial cancer expressing activating molecular FGFR aberrations | Hotte, Dr Sebastien | Suspended/On hold | NCT04045613 |
| (BMS) CA018005 / FRACTION-RCC | A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma | Hotte, Dr Sebastien | Suspended/On hold | NCT02996110 |
| (CCTG) REC.4 / EA8143 | A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients With Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC) | Hotte, Dr Sebastien | Suspended/On hold | NCT03055013 |
Find a Trial
Contact Us